Ronan Smith, a postdoctoral research fellow at Adelaide University, has been awarded the prestigious Physics in Medicine & Biology (PMB) Early Career Researcher Award for his groundbreaking work in X-ray velocimetry (XV). This award, which recognizes the best paper in PMB's 2025 Early Career Researcher Focus Collection, highlights Smith's innovative approach to understanding lung function and its potential impact on treating emphysema. Personally, I find this award particularly fascinating because it showcases how cutting-edge technology can be applied to improve medical treatments, and it raises a deeper question about the future of personalized medicine. What makes this research so intriguing is its ability to visualize and quantify lung function in unprecedented detail, offering a new perspective on how we assess and treat respiratory conditions. In my opinion, this is a significant step forward in the field of biomedical physics, and it has the potential to revolutionize the way we approach lung-related diseases. One thing that immediately stands out is the use of XV imaging to detect changes in airflow due to endobronchial valve (EBV) placement. This is a remarkable achievement, as it allows us to non-invasively measure regional and local changes in airflow, providing a more accurate assessment of the clinical impact of EBV placement. What many people don't realize is that this technology has the potential to improve the quality of life for people with emphysema, as it can help with better placement and verification of EBVs, leading to improved treatment options. If you take a step back and think about it, this research has broader implications for the field of medicine. It demonstrates the power of interdisciplinary collaboration, bringing together physicists, clinicians, and engineers to develop innovative solutions to complex medical problems. This raises a deeper question about the role of technology in healthcare, and how we can leverage it to improve patient outcomes. A detail that I find especially interesting is the use of XV LVAS software from 4DMedical to analyze the data. This software correlates motion in the XV videos with CT data to measure the lung's expansion and contraction during a breath cycle, creating a 3D map of specific ventilation. This map can then be used to calculate mean specific ventilation and ventilation heterogeneity across a given lung region, providing a comprehensive understanding of lung function. What this really suggests is that XV imaging has the potential to become a standard tool in respiratory medicine, offering a more accurate and non-invasive way to assess lung function and guide treatment decisions. Looking ahead, I'm excited to see how XV imaging will continue to evolve and be applied to other diseases. The world's first paediatric clinical trial of XV imaging, which is examining the feasibility of using the technology in children with cystic fibrosis, is a promising development. This raises a deeper question about the future of XV imaging in pediatric medicine, and how it can be used to improve outcomes for children with respiratory conditions. In conclusion, Ronan Smith's work on X-ray velocimetry is a remarkable achievement, and it has the potential to revolutionize the way we approach lung-related diseases. As a physicist working in medicine/biology, it feels like the perfect award to get, and it's great to see interest in the work we are doing. This award is a testament to the power of interdisciplinary collaboration and the potential of technology to improve patient outcomes. Personally, I believe that XV imaging has the potential to become a standard tool in respiratory medicine, and I'm excited to see how it will continue to evolve and be applied to other diseases.
